Daniel E. Geffken - Feb 14, 2024 Form 4 Insider Report for PHOENIX BIOTECH ACQUISITION CORP. (CERO)

Role
Chief Financial Officer
Signature
/s/ Chris Ehrlich, Attorney-in-Fact
Stock symbol
CERO
Transactions as of
Feb 14, 2024
Transactions value $
$0
Form type
4
Date filed
2/16/2024, 07:39 PM
Previous filing
Oct 30, 2023
Next filing
May 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERO Class A Common Stock Other +10K 10K Feb 14, 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Daniel E. Geffken is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents shares of Class A Common Stock distributed in-kind by Phoenix Biotech Sponsor, LLC (the "Sponsor") to its members, pro rata and without consideration.